• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD8 和程序性死亡配体 1 表达对可切除非小细胞肺癌患者的预后影响。

Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.

机构信息

Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, 51353, Republic of Korea.

Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, 51472, Republic of Korea.

出版信息

Br J Cancer. 2019 Mar;120(5):547-554. doi: 10.1038/s41416-019-0398-5. Epub 2019 Feb 12.

DOI:10.1038/s41416-019-0398-5
PMID:30745585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6461857/
Abstract

BACKGROUND

The prognostic impact of the expression of CD8 and programmed death-ligand 1 (PD-L1) has not been established in patients with resectable non-small cell lung cancer (NSCLC).

METHODS

Surgical tissue specimens were obtained from 136 patients with NSCLC who underwent surgical resection. The expression levels of CD8 and PD-L1 were assessed using tissue microarrays and immunohistochemistry.

RESULTS

The CD8-positive group showed significant increases in overall survival (OS) (median, not reached [NR] vs. 28.452 months) and relapse-free survival (RFS) (median, NR vs. 14.916 months) compared with the CD8-negative group. In contrast to CD8, the PD-L1-negative group demonstrated significant increases in OS (median, NR vs. 29.405 months) and RFS (median, 63.573 vs. 17.577 months) compared with the PD-L1-positive group. Two prognostic groups were stratified according to CD8/PD-L1 expression: group 1 (CD8-positive/PD-L1-negative) vs. group 2 (CD8/PD-L1: positive/positive, negative/negative, negative/positive). Group 1 had better OS (median, NR vs. 29.405 months) and RFS (median, NR vs. 17.577 months) than group 2. Multivariate analysis indicated that group 1 constituted an independent favourable prognostic factor for OS (hazard ratio [HR], 0.329, p = 0.001) and RFS (HR, 0.293; p < 0.001).

CONCLUSIONS

Positive CD8 and negative PD-L1 expression together may be favourable prognostic markers in resectable NSCLC.

摘要

背景

CD8 和程序性死亡配体 1（PD-L1）的表达对可切除的非小细胞肺癌（NSCLC）患者的预后影响尚未确定。

方法

对 136 例接受手术切除的 NSCLC 患者的手术组织标本进行了研究。使用组织微阵列和免疫组织化学评估 CD8 和 PD-L1 的表达水平。

结果

与 CD8 阴性组相比，CD8 阳性组的总生存期（OS）（中位数，未达到[NR] vs. 28.452 个月）和无复发生存期（RFS）（中位数，NR vs. 14.916 个月）均显著增加。与 CD8 相反，PD-L1 阴性组的 OS（中位数，NR vs. 29.405 个月）和 RFS（中位数，63.573 vs. 17.577 个月）均显著高于 PD-L1 阳性组。根据 CD8/PD-L1 表达情况将患者分为两组：组 1（CD8 阳性/PD-L1 阴性）和组 2（CD8/PD-L1：阳性/阳性、阴性/阴性、阴性/阳性）。组 1 的 OS（中位数，NR vs. 29.405 个月）和 RFS（中位数，NR vs. 17.577 个月）均优于组 2。多变量分析表明，组 1 是 OS（风险比[HR]，0.329，p=0.001）和 RFS（HR，0.293；p<0.001）的独立预后因素。

结论

CD8 阳性和 PD-L1 阴性的表达可能是可切除 NSCLC 的有利预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/11eff2e93ed0/41416_2019_398_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/2e8f9dd50bae/41416_2019_398_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/ce68e65d12cb/41416_2019_398_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/9d52ec5c9531/41416_2019_398_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/11eff2e93ed0/41416_2019_398_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/2e8f9dd50bae/41416_2019_398_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/ce68e65d12cb/41416_2019_398_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/9d52ec5c9531/41416_2019_398_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a212/6461857/11eff2e93ed0/41416_2019_398_Fig4_HTML.jpg

相似文献

1
Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.CD8 和程序性死亡配体 1 表达对可切除非小细胞肺癌患者的预后影响。
Br J Cancer. 2019 Mar;120(5):547-554. doi: 10.1038/s41416-019-0398-5. Epub 2019 Feb 12.
2
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.非小细胞肺癌活检的自动图像分析预测抗 PD-L1 治疗反应。
J Immunother Cancer. 2019 May 6;7(1):121. doi: 10.1186/s40425-019-0589-x.
3
Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.程序性死亡配体 1 及其周围免疫状态对Ⅰ期肺癌的预后影响。
Clin Lung Cancer. 2020 Jul;21(4):e302-e314. doi: 10.1016/j.cllc.2020.01.013. Epub 2020 Jan 27.
4
Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.程序性细胞死亡配体 1 在伴有间质性肺疾病的非小细胞肺癌患者中的表达：一项匹配病例对照研究。
Clin Lung Cancer. 2018 Sep;19(5):e667-e673. doi: 10.1016/j.cllc.2018.04.012. Epub 2018 May 5.
5
Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.PD-L1 表达状态对早期和局部晚期非小细胞肺癌患者的双相预后意义。
Cancer Immunol Immunother. 2021 Apr;70(4):1063-1074. doi: 10.1007/s00262-020-02755-w. Epub 2020 Oct 28.
6
Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.在接受同步放化疗的 III 期非小细胞肺癌患者中，PD-L1 表达与 CD8 + 肿瘤浸润淋巴细胞密度联合的预测相关性
Eur J Cancer. 2016 Mar;55:7-14. doi: 10.1016/j.ejca.2015.11.020. Epub 2016 Jan 6.
7
Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.PD-L1 和 c-Myc 在非小细胞肺癌中的表达及临床意义。
J Cancer Res Clin Oncol. 2019 Nov;145(11):2663-2674. doi: 10.1007/s00432-019-03025-8. Epub 2019 Sep 20.
8
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.PD-L1 蛋白表达作为肺鳞癌的预后因素。
Lung Cancer. 2017 Feb;104:7-15. doi: 10.1016/j.lungcan.2016.12.006. Epub 2016 Dec 12.
9
Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.评估非小细胞肺癌中的PDL-1和PD-1：一种新型免疫评分方法。
Clin Lung Cancer. 2017 Mar;18(2):220-233.e8. doi: 10.1016/j.cllc.2016.09.009. Epub 2016 Oct 5.
10
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with -Mutant Non-small Cell Lung Cancer.回顾性研究 PD-L1 表达在 - 突变型非小细胞肺癌患者中的作用。
Cancer Res Treat. 2018 Jan;50(1):95-102. doi: 10.4143/crt.2016.591. Epub 2017 Mar 17.

引用本文的文献

1
Intratumoral CD8+ tumor-infiltrating lymphocytes as prognostic predictors in radio-chemoradiotherapy-treated nasopharyngeal carcinoma.瘤内CD8 +肿瘤浸润淋巴细胞作为放化疗治疗鼻咽癌的预后预测指标
Front Oncol. 2025 May 15;15:1551980. doi: 10.3389/fonc.2025.1551980. eCollection 2025.
2
ADC histogram analysis of tumor-infiltrating CD8+ T cell levels in meningioma.脑膜瘤中肿瘤浸润性CD8 + T细胞水平的ADC直方图分析
Neurosurg Rev. 2025 Jan 10;48(1):34. doi: 10.1007/s10143-025-03197-7.
3
Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer.

本文引用的文献

1
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.PD-L1 表达和 CD8+T 细胞浸润在 EGFR 突变和 ALK 重排肺癌患者中的临床意义。
Lung Cancer. 2018 Nov;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. Epub 2018 Sep 14.
2
PD-L1 Expression and CD8 T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer.PD-L1 表达和 CD8+T 细胞浸润预测晚期胃癌的预后良好。
J Immunol Res. 2018 May 29;2018:4180517. doi: 10.1155/2018/4180517. eCollection 2018.
3
A transcriptionally and functionally distinct PD-1 CD8 T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
抑癌基因 STK11 缺失抑制非小细胞肺癌患者的脂代谢并减弱 KRAS 诱导的免疫原性。
Cancer Res Commun. 2024 Aug 1;4(8):2282-2294. doi: 10.1158/2767-9764.CRC-24-0153.
4
MRI features and tumor-infiltrating CD8 + T cells-based nomogram for predicting meningioma recurrence risk.基于 MRI 特征和肿瘤浸润 CD8+T 细胞的列线图预测脑膜瘤复发风险。
Cancer Imaging. 2024 Jun 28;24(1):79. doi: 10.1186/s40644-024-00731-6.
5
PD-L1 and PD-1 Expression in Early Stage Uterine Endometrioid Carcinoma.PD-L1 和 PD-1 在早期子宫内膜样腺癌中的表达。
In Vivo. 2024 Jan-Feb;38(1):246-252. doi: 10.21873/invivo.13431.
6
Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues.非小细胞肺癌肿瘤、肿瘤边缘、相邻和远处肺组织中 T 细胞 repertoire 的空间异质性。
Oncoimmunology. 2023 Oct 20;12(1):2233399. doi: 10.1080/2162402X.2023.2233399. eCollection 2023.
7
A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer.生物标志物及其对早期非小细胞肺癌切除术后临床影响的综述
Cancers (Basel). 2023 Sep 14;15(18):4561. doi: 10.3390/cancers15184561.
8
Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung Adenocarcinomas.微观变量与肿瘤炎性微环境不会改变Ⅰ-ⅡA期肺腺癌患者的生存率或复发情况。
Cancers (Basel). 2023 Sep 13;15(18):4542. doi: 10.3390/cancers15184542.
9
Granzyme B (GZMB)-Positive Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma: Significance as a Prognostic Factor and Association with Immunosuppressive Proteins.肺腺癌中颗粒酶B（GZMB）阳性肿瘤浸润淋巴细胞：作为预后因素的意义及与免疫抑制蛋白的关联
Ann Surg Oncol. 2023 Nov;30(12):7579-7589. doi: 10.1245/s10434-023-14085-z. Epub 2023 Aug 16.
10
Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy.肺癌合并慢阻肺患者从抗 PD-1/PD-L1 治疗中获益。
Front Immunol. 2022 Dec 1;13:1038715. doi: 10.3389/fimmu.2022.1038715. eCollection 2022.
PD-1 阻断治疗非小细胞肺癌中具有预测潜力的转录和功能不同的 PD-1 CD8 T 细胞池。
Nat Med. 2018 Jul;24(7):994-1004. doi: 10.1038/s41591-018-0057-z. Epub 2018 Jun 11.
4
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
5
Prognostic value of PD-L1 expression in combination with CD8 TILs density in patients with surgically resected non-small cell lung cancer.PD-L1 表达联合 CD8 TIL 密度对手术切除的非小细胞肺癌患者的预后价值。
Cancer Med. 2018 Jan;7(1):32-45. doi: 10.1002/cam4.1243. Epub 2017 Nov 23.
6
Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.低表达 PD-1 的细胞毒性 CD8+肿瘤浸润淋巴细胞赋予 NSCLC 免疫特惠组织微环境并具有预后和预测价值。
Clin Cancer Res. 2018 Jan 15;24(2):407-419. doi: 10.1158/1078-0432.CCR-17-2156. Epub 2017 Oct 26.
7
Aligning digital CD8 scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma.将数字 CD8 评分与程序性死亡配体 1 表达的靶向下一代测序相匹配：早期鳞状细胞肺癌中的实用方法。
Histopathology. 2018 Jan;72(2):270-284. doi: 10.1111/his.13346. Epub 2017 Nov 3.
8
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
9
Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.I期非小细胞肺癌中CD8 +肿瘤浸润淋巴细胞、程序性死亡受体配体1和Foxp3 +肿瘤浸润淋巴细胞的表达对辅助化疗决策的指导作用
Oncotarget. 2016 Sep 27;7(39):64318-64329. doi: 10.18632/oncotarget.11793.
10
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1 and CD8 tumor-infiltrating T cells and outcome.基底样鳞状细胞肺癌中PD-L1的表达：与PD-1和CD8肿瘤浸润性T细胞的关系及预后
Mod Pathol. 2016 Dec;29(12):1552-1564. doi: 10.1038/modpathol.2016.149. Epub 2016 Aug 26.